Skip Navigation

European Journal of Heart Failure 2006 8(2):216-217; doi:10.1016/j.ejheart.2006.01.004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by McLachlan, C. S.
Right arrow Articles by Mossop, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McLachlan, C. S.
Right arrow Articles by Mossop, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society of Cardiology

Levosimendan and plasma BNP levels: Do inflammatory cytokines regulate BNP in chronic decompensated heart failure?

Craig S. McLachlan* and Peter Mossop

Department of Medical Imaging, St. Vincent's Hospital Melbourne, Australia

* Corresponding author. E-mail address: reperfusion@hotmail.com

Received September 18, 2005;
The first 10% of the full text of this article appears below.

We read with interest the recent study by Moertl et al. [1]. In this study the investigators demonstrated that in chronic decompensated heart failure patients, therapeutic PGE1 as opposed to levosimendan produced a sustained reduction in plasma B-type natriuretic peptide (BNP) levels. This finding suggests that PGE1 would be superior to levosimendan in treating decompensated heart failure on the basis of a . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?